Doms № 5 -2023

 

https://doi.org/10.57105/2415-7252-2023-5-04

Нові можливості нефропротекції при цукровому діабеті 2-го типу з використанням фінеренону

Консенсус ради експертів

New possibilities of nephroprotection in type 2 diabetes using finerenone

Consensus of the board of experts

Mankovsky BM, Bilchenko OV, Dudar IO, Zaichenko HZ, Ivanov DD, Komisarenko YI, Sayen-ko YA, Sokolova LK, Urbanovych AM, Yuzvenko TY, Kravchenyuk EY

Abstract

Patients with chronic kidney disease (CKD) belong to the category of patients with diabetes mellitus (DM), which are the most difficult to treat. They require a multidisciplinary, multifactorial approach to slow disease progression, reduce glomerular filtration rate (GFR), and prevent cardiovascular morbidity and mortality. Modern treatment of CKD in patients with type 2 diabetes involves influencing various links of its pathogenesis. The use of finerenone is a fundamentally new approach in treatment of CKD. Inflammation and fibrosis, which develop as a result of excessive activation of mineralocorticoid receptors, are key pathophysiological mechanisms of the development and progression of CKD in patients with type 2 DM. Therefore, the blocking of mineralocorticoid receptors (MCR) with the innovative nonsteroidal selective MCR antagonist finerenone is a promising way to improve the clinical course of CKD, and has a favorable prognostic effect on the rate of progression of CKD and on the risk of cardiovascular events. The feasibility of adding finerenone to the treatment regimens of patients with CKD and type 2 diabetes in order to reduce the rate of progression of CKD and reduce the frequency of cardiovascular events is substantiated by convincing data from clinical studies and reflected in the recommendations of the American Diabetes Association, 2023. The innovative drug finerenone has a direct nephroprotective effect, which reliably slows down the progression of CKD in patients with type 2 diabetes. Therefore, finerenone should be considered for prescribing from the initial stage of kidney damage. When using finerenone, the risk of developing hyperkalemia is low, which minimizes the risk of withdrawal of the drug during treatment. Despite the available modern methods of treatment, which are primarily aimed at the hemodynamic and metabolic factors of the development of CKD in type 2 diabetes mellitus, the introduction of the specified new pathogenetic approach using finerenone, as a means whose mechanism of action is due to a direct effect on inflammation and fibrosis, is considered necessary from the point of view of improving the clinical course of CKD and the prognosis.

Key words: chronic kidney disease, type 2 diabetes mellitus, finerenone, cardiovascular morbidity, mortality

  1. Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin. J. Am. Soc. Nephrol. 2017;12(12):2032‒45. DOI: 10.2215/ CJN.11491116. PMID: 28522654
  2. Mora-Fernández C, et al. J Physiol 2014;18:3997
  3. Bauersachs J, et al. Hypertension 2015;65:257–263
  4. Menn-Josephy H, et al. Am J Nephrol 2016;44:289–299. doi: 10.1159/000449511
  5. Маньковський Б. М. та співавт. Консенсус з лікування пацієнтів із цукровим діабетом 2-го типу у поєднанні з серцево-судинними та/або нирковими захворюваннями. ДОМС № 3 (XI) 2022 с.8-21
  6. Kidney, Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;98, s1-s115
  7. International Diabetes Federation 2019. IDF Diabetes Atlas, 9th edn. https://diabetesatlas.org/en/ [accessed 16 Mar 2020]
  8. Wu B, et al. BMJ Open Diabetes Res Care 2016;4:e000154
  9. Wen C.P. et al. Kidney Int 2017;92:388–396. doi: 1016/j.kint.2017.01.030
  10. Afkarian M, et al. J Am Soc Nephrol 2013;24:302–308
  11. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease; 2022. KidneyInternational(2022)102(Suppl5S),S1–S127
  12. Shlipak MG, et Kidney Int. 2021 Jan;99(1):34-47. doi: 10.1016/j.kint.2020.10.012
  13. KDIGO, CKD workgroup. Kidney Int Supp 2013;3:1–150
  14. American Diabetes Association Professional Practice Committee. Diabetes Care 2022;45(Suppl 1):S175–S184
  15. Cosentino F, et al. Eur Heart J 2020;41:255–323
  16. United States Renal Data System. USRDS annual data report Volume 1, Chapter 2.
  17. Hellemons ME, et al. Nephrol Dial Transplant 2013;28:706–715
  18. Assogba GF, et al. Diabetes Metab 2012;38:558–566
  19. NHS Diabetes Audit. 2017–2018 Full report.
  20. Lunney M, et al. Kidney Int Suppl 2018;8;30–40; 2. Bello AK, et al. JAMA 2017;317:1864–1881
  21. American Diabetes Association (ADA) Standards of Care in Diabetes—2023. Diabetes Care December 2022, Vol.46, S5-S9. doi:https://doi.org/10.2337/dc23-Srev
  22. 2019 Guidelines on Diabetes, Pre-Diabetes and Cardiovascular Diseases developed in collaboration with the EASD. European Heart Journal, Volume 41, Issue 2, 7 January 2020, Pages 255–323, https://doi.org/10.1093/eurheartj/ehz486
  23. Zanchi A, et al. Diabetic kidney disease in type 2 diabetes: a consensus statement from the Swiss Societies of Diabetes and Nephrology. Swiss Med Wkly. 2023;153:40004. doi:10.57187/smw.2023.40004
  24. Brenner B, et al. N Engl J Med. 2001;345(12):861-869
  25. Lewis EJ, et al. N Eng J Med. 2001;345(12):851-860, https://pubmed.ncbi.nlm.nih.gov/11565518/
  26. ABCD and Renal Association Clinical practice guidelines for management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease (DKD): https://abcd.care/sites/abcd.care/files/site_uploads/Resources/Position-Papers/Management-of-hypertension-and-RAAS-blockade-in-adults-with-DKD.pdf
  27. ABCD Guideline on the Management of lipids in people with diabetes and kidney disease: https://abcd.care/sites/abcd.care/files/site_uploads/Resources/Position-Papers/Management-of-lipids-in%20adults-with-DKD.pdf
  28. Perkovic V, et al. N Engl J Med. 2019. doi: 10.1056/NEJMoa1811744, https://www.nejm.org/doi/pdf/10.1056/NEJMoa1811744
  29. Heerspink HJL, et al. N Engl J Med 2020;383:1436–1446, https://www.nejm.org/doi/full/10.1056/NEJMoa2024816
  30. Lewis EJ, et al. N Engl J Med 2001;345:851–860
  31. Shunan F, et al. J Renin Angiotensin Aldosterone Syst 2018;19:1470320318803495
  32. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJ, Charytan DM, et al.; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019 Jun; 380(24): 2295–306
  33. Sternlicht H, Bakris GL. The kidney in hypertension. Med Clin North Am. 2017 Jan; 101(1): 207–17. 11 Blasi ER, Rocha
  34. Kolkhof P. et al. Pharmacol Res. 2021;172:105859. doi: 10.1016/j.phrs.2021.105859
  35. Kolkhof P, et al. Handb Exp Pharmacol 2017;243:271–305
  36. Nagase M & Fujita T. Nat Rev Nephrol 2013;9:86–98
  37. Brown NJ. Nat Rev Nephrol 2013;9:459–469
  38. Barrera-Chimal J, et al. Kidney Int 2019;96:302–309
  39. Ong GS & Young MJ. J Mol Endocrinol 2017;58:R33–R57
  40. Capelli I, et al. J Nephrol 2019; doi: 10.1007/s40620-019-00600-7
  41. Buonafine M, et al. Am J Hypertension 2018;31:1165–1174
  42. Biwer LA, et al. Am J Hypertension 2019;32:123–134
  43. Amazit L, et al. J Biol Chem 2015;290:21876–21889
  44. Fagart J, et al. J Biol Chem 2010;285:29932–29940
  45. Epstein M. Am J Nephrol. 2021;52(3):209-216. doi: 10.1159/000515622.
  46. Epstein M. Kidney Int. Supl. 2022;12:1–6. doi: 10.1016/j.kisu.2021.11.007.
  47. Epstein M. Diabetes Ther. 2022;13(4):583-588. doi: 10.1007/s13300-022-01236-w
  48. American Diabetes Association. Diabetes Care. 2023;46(Supplement_1):S191-S202. doi: 10.2337/dc23-S011
  49. Kolkhof P, et al. J Cardiovasc Pharm 2014;64–69
  50. Grune J, et al. Hypertension 2018;71:599–608;
  51. Lattenist L, et al. Hypertension 2017;69:870–878;
  52. Barrera-Chimal J, et al. Kidney Int 2018;93:1344–1355
  53. Bakris GL, et al. JAMA 2015;314:884–894
  54. George L. Bakris et al. N Engl J Med 2020;383:2219-29. DOI: 10.1056/NEJMoa2025845
  55. Alicic RZ, et al. Adv Chronic Kidney Dis 2018;25:1941–191
  56. Joseph JJ et al. Circulation. 2022;145(9):e722-e759. doi: 10.1161/CIR.0000000000001040
  57. Blonde L et al. Endocr Pract. 2022;28(10):923-1049. doi: 10.1016/j.eprac.2022.08.002
  58. Ian H. De Boer et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 2022. https://doi.org/10.2337/dci22-0027
  59. Tzukroviy diabet. Klinichna nastanova, zasnovana na dokazah. Ministerstvo ohorony zdorov`ya; ukrainskiy naukovo-practichniy centr endocrinnoyi hirurgiyi, transplantaciyi endoctinniyh organiv i tkanin Ministerstvo ohorony zdorov`ya Ukrainy 2022.
  60. Uniphikovaniy klinichniy protokol pervinnoyi ta vtorinnoyi (specializovanoyi) medichnoyi dopomogy tzukroviy diabet 2 typu. Nakaz Ministerstva ohorony zdorov`ya 21 grudnya 2012 No1118.
  61. Tzukroviy diabet 2 typu. Adaptovanaklinichna nastanova, zasnovana na dokazah. Nakaz Ministerstva ohorony zdorov’ya 21 grudnya 2012 No1118.
  62. Tomaschitz, A., Pilz, S., Ritz, E., Obermayer-Pietsch, B., and Pieber, T. R. (2010) Aldosterone and arterial hypertension. Rev. Endocrinol. 6, 83–93
  63. Rossi, G. P., Bernini, G., Desideri, G., Fabris, B., Ferri, C., Giacchetti, G., Letizia, C., Maccario, M., Mannelli, M., Matterello, M.-J., Montemurro, D., Palumbo, G., Rizzoni, D., Rossi, E., Pessina, A. C., Mantero, F., and PAPY Study Participants (2006) Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 48, 232–238
  64. Heerspink HJL, Stef_ansson BV, Correa-Rotter R, et al.; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl JMed 2020;383:1436–1446
  65. G. Herrington, N. Staplin, C. Wanner et al.; Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2023;388:117-27. DOI: 10.1056/NEJMoa2204233

https://icd.who.int/browse10/2015/en#/E11.2